The NCI Radiation Oncology Branch and the NHLBI Laboratory of Single Molecule Biophysics seek parties to co-develop fluorescent nanodiamonds for use as in vivo and in vitro optical tracking probes toward commercialization.
National Cancer Institute (NCI) researchers have isolated T cell receptors (TCRs) reactive to the highly prevalent p53-R175H mutant in the context of the human leukocyte antigen (HLA) class II allele, HLA-DRB1*13:01. These TCRs can be used for a variety of therapeutic, diagnostic, and research applications. NCI seeks licensing and/or co-development research collaborations for TCRs that recognize the p53-R175H mutation and the associated HLA allele, and methods for identifying p53 mutation-reactive T cell receptors.
The Biorepositories and Biospecimen Research Branch (BBRB) at the National Cancer Institute (NCI) has sponsored various initiatives for conducting biospecimen research. Through these initiatives, NCI seeks to advance biospecimen science and improve research reproducibility by investigating how different biospecimen collection, handling and processing procedures affect biospecimen molecular profiles. BBRB is seeking collaborators to extend these studies.